FBRX is the ticker symbol for Forte Biosciences, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks FBRX with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is FBRX a good stock to buy?

FBRX is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/FBRX.

Where does 13F Pro source FBRX data?

All Forte Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Forte Biosciences, Inc. files with the SEC under CIK 1419041. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Forte Biosciences, Inc.(FBRX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Forte Biosciences, Inc. (FBRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. FBRX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $18.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Forte Biosciences, Inc. reports net income of $-23.3M, free cash flow of $-22.7M. Top institutional holders of FBRX by reported 13-F value include FEDERATED HERMES, ORBIMED ADVISORS, FRED ALGER MANAGEMENT, based on the most recent SEC filings. FBRX trades on the Nasdaq exchange and files with the SEC under CIK 1419041. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FBRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Forte Biosciences, Inc. directly from SEC EDGAR.

Net Income

$-23.3M

Free Cash Flow

$-22.7M

FBRX key financials by period

Forte Biosciences, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2019	10-K	$36.0K	$-4.1M	—
FY 2018	10-K	$18.0M	$-49.0M	—
FY 2017	10-K	$41.0K	$-38.9M	—
FY 2016	10-K	$49.0K	$-33.5M	—

Institutions holding FBRX

Institutional investors reporting a position in Forte Biosciences, Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
FEDERATED HERMES	2,110,516	$44.8M	2026-06-30
ORBIMED ADVISORS	1,577,705	$33.5M	2026-06-30
FRED ALGER MANAGEMENT	1,439,697	$30.6M	2026-06-30
Jupiter Topco	1,373,060	$29.2M	2026-06-30
BlackRock	1,222,862	$26.0M	2026-06-30
Affinity Asset Advisors	1,145,391	$24.3M	2026-06-30
MPM BioImpact	987,448	$21.0M	2026-06-30
TCG Crossover Management	920,000	$19.6M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	861,737	$18.3M	2026-06-30
Woodline Partners	712,753	$15.1M	2026-06-30

SEC EDGAR: CIK 1419041 →

Forte Biosciences, Inc.

FBRX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $18.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.